Recombinant Human IDE, His-tagged
Cat.No. : | IDE-117H |
Product Overview : | Recombinant Human Insulin-Degrading Enzyme/IDE is produced by our mammalian expression system in human cells. The target protein is expressed with sequence (Met42-Leu1019) of Human IDE fused with a 6His tag at the C-terminus. |
- Specification
- Gene Information
- Related Products
Description : | This gene encodes a zinc metallopeptidase that degrades intracellular insulin, and thereby terminates insulins activity, as well as participating in intercellular peptide signalling by degrading diverse peptides such as glucagon, amylin, bradykinin, and kallidin. The preferential affinity of this enzyme for insulin results in insulin-mediated inhibition of the degradation of other peptides such as beta-amyloid. Deficiencies in this protein''s function are associated with Alzheimer''s disease and type 2 diabetes mellitus but mutations in this gene have not been shown to be causitive for these diseases. This protein localizes primarily to the cytoplasm but in some cell types localizes to the extracellular space, cell membrane, peroxisome, and mitochondrion. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants have been described but have not been experimentally verified. |
Source : | HEK293 |
Species : | Human |
Tag : | His |
AA Sequence : | MNNPAIKRIGNHITKSPEDKREYRG LELANGIKVLLISDPTTDKSSAALD VHIGSLSDPPNIAGL SHFCEHMLFLGTKKYPKENEYSQFL SEHAGSSNAFTSGEHTNYYFDVSHE HLEGALDRFAQFFLC PLFDESCKDREVNAVDSEHEKNVMN DAWRLFQLEKATGNPKHPFSKFGTG NKYTLETRPNQEGID VRQELLKFHSAYYSSNLMAVCVLGR ESLDDLTNLVVKLFSEVENKNVPLP EFPEHPFQEEHLKQL YKIVPIKDIRNLYVTFPIPDLQKYY KSNPGHYLGHLIGHEGPGSLLSELK SKGWVNTLVGGQKEG ARGFMFFIINVDLTEEGLLHVEDII LHMFQYIQKLRAEGPQEWVFQECKD LNAVAFRFKDKERPR GYTSKIAGILHYYPLEEVLTAEYLL EEFRPDLIEMVLDKLRPENVRVAIV SKSFEGKTDRTEEWY GTQYKQEAIPDEVIKKWQNADLNGK FKLPTKNEFIPTNFEILPLEKEATP YPALIKDTAMSKLWF KQDDKFFLPKACLNFEFFSPFAYVD PLHCNMAYLYLELLKDSLNEYAYAA ELAGLSYDLQNTIYG MYLSVKGYNDKQPILLKKIIEKMAT FEIDEKRFEIIKEAYMRSLNNFRAE QPHQHAMYYLRLLMT EVAWTKDELKEALDDVTLPRLKAFI PQLLSRLHIEALLHGNITKQAALGI MQMVEDTLIEHAHTK PLLPSQLVRYREVQLPDRGWFVYQQ RNEVHNNCGIEIYYQTDMQSTSENM FLELFCQIISEPCFN TLRTKEQLGYIVFSGPRRANGIQGL RFIIQSEKPPHYLESRVEAFLITME KSIEDMTEEAFQKHI QALAIRRLDKPKKLSAECAKYWGEI ISQQYNFDRDNTEVAYLKTLTKEDI IKFYKEMLAVDAPRR HKVSVHVLAREMDSCPVVGEFPCQN DINLSQAPALPQPEVIQNMTEFKRG LPLFPLVKPHINFMA AKLLDHHHHHH |
Endotoxin : | Less than 0.1 ng/μg (1 IEU/μg). |
Purity : | Greater than 95% as determined by reducing SDS-PAGE. |
Gene Name : | IDE insulin-degrading enzyme [ Homo sapiens (human) ] |
Official Symbol : | IDE |
Synonyms : | IDE; INSULYSIN; insulin-degrading enzyme; insulinase; insulin protease; Abeta-degrading protease; NP_001159418.1; EC 3.4.24.56; NP_004960.2; EC 3.4.24.56 |
Gene ID : | 3416 |
mRNA Refseq : | NM_001165946 |
Protein Refseq : | NP_001159418 |
MIM : | 146680 |
UniProt ID : | P14735 |
Chromosome Location : | 10q23-q25 |
Pathway : | Alzheimer''s disease |
Function : | ATP binding; ATPase activity; beta-amyloid binding |
Products Types
◆ Recombinant Protein | ||
IDE-1133H | Recombinant Human IDE Protein, His (Fc)-Avi-tagged | +Inquiry |
Ide-1644M | Recombinant Mouse Ide Protein, His-tagged | +Inquiry |
IDE-07H | Active Recombinant Human IDE Protein (42-1019aa), C-His tagged | +Inquiry |
Ide-1211M | Recombinant Mouse Ide Protein, MYC/DDK-tagged | +Inquiry |
IDE-2011R | Recombinant Rhesus Macaque IDE Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
IDE-5308HCL | Recombinant Human IDE 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionSide effects of IDE treatment include pain at the implant site, displacement or rupture of the electrodes, and irritation discomfort. However, these side effects are usually rare and can be relieved by adjusting stimulation parameters or procedures.
The principle of IDE pain treatment is to inhibit or regulate the transmission of pain signals by sending electrical stimulation signals to the spinal cord or peripheral nerves, thereby reducing pain sensation.
The advantages of IDE treatment include non-drug, non-surgical, reversible, etc. It is effective in relieving pain, improving quality of life, and does not require long-term medication or surgical treatment.
A detailed physical examination and evaluation is required prior to IDE treatment to ensure that the patient is suitable for IDE treatment. At the same time, it is also necessary to prepare relevant surgical instruments and drugs.
IDE treatment process involves implanting electrodes, connecting the stimulator, adjusting the stimulation parameters and procedures, and regular check-ups and adjustments.
After IDE treatment, you need to pay attention to maintaining good lifestyle habits and avoid overwork and strenuous exercise. In addition, regular check-ups and adjustments to stimulation parameters and procedures are required to ensure optimal treatment outcomes.
Customer Reviews (3)
Write a reviewIDE protein has a long shelf life, which facilitates the continuity of subsequent experiments.
IDE has shown good biocompatibility and safety in relevant experiments.
The IDE shows excellent stability and repeatability under certain experimental conditions.
Ask a Question for All IDE Products
Required fields are marked with *
My Review for All IDE Products
Required fields are marked with *
Inquiry Basket